Case Study
Determining the appropriate price for new treatments can be challenging, especially for innovative therapies which elevate the standard of patient care.
An EU-based biotechnology company with a novel drug in development approached Medicus with a question: how should we price a game-changing therapy in a disease area that has not experienced significant innovation in over two decades?
Our research included:
Conducted in-depth qualitative interviews with physicians to better understand current clinical practices and disease management strategies
Assessed the current and future competitive landscape through a combination of stakeholder interviews, data analysis, and literature / pipeline research
Reviewed pricing for comparable treatments in similar disease areas
Analyzed real-world data across multiple private and public payers to estimate the burden of disease across settings of care
Conducted primary research with payers to better understand price expectations and insurance coverage mix across patients
Developed materials to support value communication across economic decision-makers
Armed with a clear picture of the patient journey, treatment landscape, and pricing / access expectations, our client determined an optimal US treatment price for its therapy.
We took a multifaceted approach to answering our client’s novel question.
We enabled our client to optimize their US pricing strategy for a novel therapy.
Outputs from our research generated robust evidence that supported our client in communicating the value of their product to economic decision-makers.